We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Cholesterol-Lowering Drugs May Lack Statins' Side Effects

By LabMedica International staff writers
Posted on 17 Mar 2011
A new generation of cholesterol-lowering drugs may be based on inhibitors of the enzyme squalene monooxygenase.

The current drugs of choice for reducing cholesterol levels, the statins, act by blocking the activity of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR). More...
Although statins are quite effective at reducing cholesterol, they are associated with potentially severe side effects such as intense muscle pain. These side effects may be due to the fact that blocking HMGR disrupts cholesterol production very early in the metabolic process. Squalene monooxygenase, on the other hand, forms a checkpoint much farther down the pathway where it uses NADPH and molecular oxygen to oxidize squalene to 2,3-oxidosqualene (squalene epoxide). At this point, it catalyzes the first oxygenation step in sterol biosynthesis, and is thought to be one of the rate-limiting enzymes in this pathway.

Another important point stressed in a paper published in the March 1, 2011, issue of the journal Cell Metabolism was that the activity of squalene monoxygenase was regulated by cholesterol itself and not by reaction byproducts or cofactors.

"Cholesterol has developed something of a bad name; so many people do not realize that it is actually essential for a healthy body. It is needed, for example, to make sex hormones and to help build the walls of every single cell in our bodies,” said senior author Dr. Andrew Brown, professor of biotechnology and biomolecular sciences at the University of New South Wales (Sydney, Australia). "The class of drugs most commonly used to lower cholesterol - statins – are the blockbusters of the pharmaceutical world and work by inhibiting HMGR. But HMGR is involved very early on in the assembly line, so inhibiting it affects all the other steps down the line – and other useful products it provides - and that can give rise in some people to unwanted side-effects, such as muscle pain.”

"What is exciting about this previously overlooked squalene monooxygenase enzyme is that it acts as a checkpoint much further down the assembly line, which should mean that it can be more specifically targeted at cholesterol production instead and leave the early part of the assembly line undisturbed,” said Dr. Brown.

Related Links:
University of New South Wales






Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.